Analyst firms · Morgan Stanley · ADGI
Morgan Stanley ADGI price target and rating history
Adagio Therapeutics Inc. (ADGI) · Health Care
Morgan Stanley rates Adagio Therapeutics Inc. (ADGI) Underweight with a $6 price target, as of its latest action on Jan 6, 2022. It has published 5 rating actions on ADGI since August 2021, including 1 upgrade and 3 downgrades.
- Current rating
- Underweight
- Price target
- $6
- Median target, all firms
- Too few
- Actions on ADGI
- 5
Morgan Stanley price target on ADGI
Every Morgan Stanley rating on ADGI
- Jan 6, 2022
- Jan 6, 2022
- Dec 15, 2021
- Nov 29, 2021
- Aug 31, 2021
Questions about Morgan Stanley and ADGI
- What is Morgan Stanley's price target for ADGI?
- Morgan Stanley's latest stated price target for Adagio Therapeutics Inc. (ADGI) is $6, from its action on Jan 6, 2022.
- What is Morgan Stanley's rating on ADGI?
- Morgan Stanley rates ADGI Underweight, a bearish rating, as of Jan 6, 2022.
- When did Morgan Stanley last change its view on ADGI?
- On Jan 6, 2022, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $11 to $6.
All Morgan Stanley ratingsADGI news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.